161 related articles for article (PubMed ID: 38612711)
21. Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
Kawai M; Nakashima A; Kamada S; Kikkawa U
J Biomed Sci; 2015 Jul; 22(1):48. PubMed ID: 26141684
[TBL] [Abstract][Full Text] [Related]
22. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple negative breast cancer cell proliferation and chemoresistance.
Lin LF; Li YT; Han H; Lin SG
Aging (Albany NY); 2021 Jan; 13(3):3945-3956. PubMed ID: 33428601
[TBL] [Abstract][Full Text] [Related]
24. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
25. Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer.
Skov N; Alves CL; Ehmsen S; Ditzel HJ
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077449
[TBL] [Abstract][Full Text] [Related]
26. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.
Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P
Oncology; 2019; 97(1):1-6. PubMed ID: 30939479
[TBL] [Abstract][Full Text] [Related]
27. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
[TBL] [Abstract][Full Text] [Related]
28. Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.
Liverani C; De Vita A; Spadazzi C; Miserocchi G; Cocchi C; Bongiovanni A; De Lucia A; La Manna F; Fabbri F; Tebaldi M; Amadori D; Tasciotti E; Martinelli G; Mercatali L; Ibrahim T
Mol Oncol; 2022 Feb; 16(4):921-939. PubMed ID: 34109737
[TBL] [Abstract][Full Text] [Related]
29. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
30. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
Prado-Vázquez G; Gámez-Pozo A; Trilla-Fuertes L; Arevalillo JM; Zapater-Moros A; Ferrer-Gómez M; Díaz-Almirón M; López-Vacas R; Navarro H; Maín P; Feliú J; Zamora P; Espinosa E; Fresno Vara JÁ
Sci Rep; 2019 Feb; 9(1):1538. PubMed ID: 30733547
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
32. SUV39H1 Expression as a Guideline for Omitting Radiotherapy in Lymph Node-positive Triple-negative Breast Cancer Patients.
Huang WL; Luo CW; Lin HS; Hung CM; Chen FM; Moi SH; Pan MR
Cancer Genomics Proteomics; 2023; 20(6):582-591. PubMed ID: 37889057
[TBL] [Abstract][Full Text] [Related]
33. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
34. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
35. [Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer].
Ma T; Zhang J; Wu J; Tang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 May; 39(5):488-95. PubMed ID: 24921394
[TBL] [Abstract][Full Text] [Related]
36. CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer.
Dai M; Zhang C; Ali A; Hong X; Tian J; Lo C; Fils-Aimé N; Burgos SA; Ali S; Lebrun JJ
Sci Rep; 2016 Oct; 6():35383. PubMed ID: 27759034
[TBL] [Abstract][Full Text] [Related]
37. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
38. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
39. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
[TBL] [Abstract][Full Text] [Related]
40. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients.
Vasiyani H; Mane M; Rana K; Shinde A; Roy M; Singh J; Gohel D; Currim F; Srivastava R; Singh R
Apoptosis; 2022 Dec; 27(11-12):961-978. PubMed ID: 36018392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]